The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Locally advanced or metastatic UC in adults who are not eligible for cisplatin-containing ChT and whose tumours express PD-L1 with a CPS ≥10KEYNOTE-052
Genitourinary Cancers
Urothelial Carcinoma
PD-L1 CPS ≥10%
KEYNOTE-052
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pembrolizumab
-
Investigator’s choice of ChT (paclitaxel, docetaxel or vinflunine)
Locally advanced or metastatic UC in adults who have received prior platinum-containing ChTKEYNOTE-045
Genitourinary Cancers
Urothelial Carcinoma
-
KEYNOTE-045
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivolumab
-
Placebo
Adjuvant therapy for adult patients with oesophageal or gastroesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy CheckMate 577
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
-
CheckMate 577
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Sotorasib
-
Single arm
Treatment of adults with advanced non-small cell lung cancer with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy CodeBreaK 100
Thoracic Malignancies
Non-small-cell Lung Cancer
KRAS G12C mutated
CodeBreaK 100
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Cemiplimab
-
Single arm (Phase II)
Treatment of basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI) Study 1620
Skin Cancers
Basal Cell Carcinoma
-
Study 1620
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Nivo/Ipi (nivolumab and ipilimumab)
-
Single arm (Phase II)
Treatment of adult patients with dMMR or MSI-H mCRC after prior fluoropyrimidine-based combination ChT CheckMate142
Gastrointestinal Cancers
Colorectal Cancer
dMMR or MSI-H
CheckMate142
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pemetrexed
Cisplatin
Cisplatin
In combination with cisplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesotheliomaEMPHACIS
Thoracic Malignancies
Pleural mesothelioma
-
EMPHACIS
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Lenvatinib
Pembrolizumab
Sunitinib
Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatmentCLEAR
Genitourinary Cancers
Renal cell cancer
-
CLEAR
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pembrolizumab
ChT (paclitaxel + carboplatin)
Placebo plus ChT (paclitaxel + carboplatin)
In combination with ChT as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrenceKEYNOTE-522
Breast Cancer
Early Breast Cancer
Triple-negative
KEYNOTE-522
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Enfortumab vedotin
-
Investigator-chosen ChT (standard docetaxel, paclitaxel or vinflunine)
Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitorEV-301
Genitourinary Cancers
Urothelial Carcinoma
-
EV-301
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
-
Single arm (Phase II)
Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomyKEYNOTE-057
Genitourinary Cancers
Urothelial Carcinoma
-
KEYNOTE-057
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Nivolumab
Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX)
ChT (FOLFOX or CAPOX)
First-line treatment for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and oesophageal adenocarcinoma CheckMate 649
Gastrointestinal Cancers
Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma
-
CheckMate 649
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Nivolumab
Fluoropyrimidine and platinum ChT (FOLFOX or CAPOX)
ChT (FOLFOX or CAPOX)
First‑line treatment for patients with HER2‑negative advanced or metastatic gastric, gastroesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥5CheckMate 649
Gastrointestinal Cancers
Gastric or gastroesophageal junction cancer and oesophageal adenocarcinoma
HER2- PD-L1 CPS ≥5
CheckMate 649
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pralsetinib
-
Single arm
Treatment for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved testARROW
Thoracic Malignancies
Non-small-cell Lung Cancer
RET fusion-positive
ARROW
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pralsetinib
-
Single arm
Treatment for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitorARROW
Breast Cancer
Non-small-cell Lung Cancer
RET fusion-positive
ARROW
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pembrolizumab
-
Single arm cohort study
Patients with unresectable or metastatic dMMR/MSI-H solid tumours that have progressed following prior treatment and have no alternative treatment options KEYNOTE-158 - Cohort K
dMMR/MSI-H solid tumour
-
dMMR/MSI-H
KEYNOTE-158 - Cohort K
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Trastuzumab
ChT (cisplatin + capecitabine or 5-FU)
ChT
HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction in patients who have not received prior anti-cancer treatment for their metastatic diseaseToGA
Gastrointestinal Cancers
Stomach or gastroesophageal junction cancer
HER2+
ToGA
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Ivosidenib
-
Placebo
For adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.ClarIDHy
Gastrointestinal Cancers
Cholangiocarcinoma
IDH1
ClarIDHy
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Mobocertinib
-
Single arm
Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, with progression on or after platinum-based ChTStudy 101
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+ exon 20 insertion mutations
Study 101
2
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
2
Tisotumab vedotin
-
Single arm (Phase II)
Adult patients with recurrent or metastatic cervical cancer with disease progression on or after ChTinnovaTV 204
Gynaecological Malignancies
Cervical Cancer
-
innovaTV 204
2
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
2
Trifluridine/Tipiracil (TAS-102)
-
Placebo
Treatment of patients with mCRC in patients who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based ChT, anti-VEGF agents and anti-EGFR agents RECOURSE
Gastrointestinal Cancers
Colorectal Cancer
-
RECOURSE
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Pembrolizumab
-
ChT ((5-fluorouracil–based therapy with or without bevacizumab or cetuximab)
First-line treatment of adults with MSI-H or dMMR mCRCKEYNOTE-177
Gastrointestinal Cancers
Colorectal Cancer
dMMR or MSI-H
KEYNOTE-177
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Cabozantinib
-
Placebo
Treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapyCOSMIC-311
Endocrine Tumours
Thyroid cancer - differentiated
-
COSMIC-311
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Pralsetinib
-
Single arm
Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC who require systemic therapyARROW
Endocrine Tumours
Thyroid Cancer - medullary
RET-mutant
ARROW
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pralsetinib
-
Single arm
Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic therapy and who are RAI-refractoryARROW
Endocrine Tumours
Thyroid cancer - differentiated
RET fusion-positive
ARROW
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Atezolizumab
-
Best supportive care
Adjuvant treatment following resection and platinum-based ChT for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥1% of tumor cellsIMpower010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥1%
IMpower010
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Pembrolizumab
ChT with our without bevacizumab
Placebo + ChT with our without bevacizumab
Persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1 KEYNOTE-826
Gynaecological Malignancies
Cervical Cancer
PD-L1 (CPS ≥1)
KEYNOTE-826
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Cisplatin and 5-FU
Placebo + cisplatin and 5-FU
First-line treatment locally advanced or metastatic oesophageal or gastroesophageal junction carcinoma that is not amenable to surgical resection or definitive CRT in combination with platinum- and fluoropyrimidine-based ChTKEYNOTE-590
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
HER2- GEJ (all randomized)
KEYNOTE-590
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Pembrolizumab
Platinum and fluoropyrimidine-based chemotherapy
Placebo + cisplatin and 5-FU
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD-L1 with a CPS ≥ 10KEYNOTE-590
Gastrointestinal Cancers
Oesophageal Cancer
PD-L1 CPS ≥10
KEYNOTE-590
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pembrolizumab
Cisplatin and 5-FU ChT
Placebo + cisplatin and 5-FU ChT
First-line treatmentKEYNOTE-590
Gastrointestinal Cancers
Oesophageal or gastroesophageal carcinoma
HER2- GEJ (squamous cell)
KEYNOTE-590
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.